Ragu Raman is the President & Chief Executive Officer of INT, responsible for all corporate functions. Prior to joining INT, Mr. Raman worked at Ortho Clinical Diagnostics for five years, most recently as the Head of R&D for Instrument Platforms addressing Clinical Labs & Transfusion Medicine. In this role, he was responsible for leading the technology strategy, product development, and continuous improvements. Prior to joining Ortho, Mr. Raman was the Vice President of R&D at STERIS Corporation for Infection Prevention Technologies serving the Healthcare and Life Science business segments. Mr. Raman also has served as R&D Director at Philips Healthcare in the CT Imaging Systems business, where he led Systems Engineering, and Gantry / X-Ray subsystems development. Mr. Raman also served in multiple positions within GE Healthcare Interventional Cardiology, Surgery and Digital Radiology businesses. Mr. Raman has a Bachelors in Engineering from the Birla Institute of Technology & Science, India and a Masters in Software Engineering from Kansas State University.
Pamela Dwyer is the Director of Manufacturing Operations, leading efforts to manufacture and scale up production to meet projected goals. Pam has over 20 years of manufacturing experience. She has worked
in many industries including medical devices, automotive, printing, sealing, machining, communications, and packaging. In her years of experience, she has been able to focus on lean and continuous improvement.
She has made many process improvements and was able to implement lean thinking and mindset into multiple facilities. Pam was last a plant manager of a 24/7 operation in which she was responsible for leading the manufacturing operations, including planning, scheduling, maintenance, budgeting, and quality.
Prior to that Pam has had many roles in engineering and lean capacity. Including starting up and running lean initiatives. Pam has a Bachelors in Industrial and Systems Engineering and an MBA from Rochester
Institute of Technology.
Michael is the Chief Innovation Officer, as well as a member of the Board. He has a PhD in molecular biology from Northwestern University and completed a post-doctoral fellowship in the Department of Microbiology at the University of Illinois Medical Center. After completing his JD at Cornell University, he practiced as a patent attorney at Nixon Peabody, LLP in Rochester. While at Nixon Peabody, he played a significant role in developing the licensing strategy for a major genetic sequencing enterprise, as well as patenting and licensing technologies for several other companies and universities.
Robert Geen is currently Head of Business Development, leading efforts to develop the go-to-market strategy and incorporate voice-of-customer input into the companies design processes. Before joining INT, Mr. Geen worked at Ortho-Clinical Diagnostics for 30 years in a variety of leadership roles in customer support, sales, and marketing, most recently as Worldwide Director of Product Management. In this role, he developed an external partnership strategy with multiple worldwide suppliers that resulted in the market introduction of over 20 new assays on Chemistry and Immunoassay Systems. Prior to that role, he led a worldwide marketing team that developed the global positioning, market introduction, and launch of multiple new clinical laboratory systems, assay technology, and test menu including the voice of customer input to the design team and the planning, execution, pre-launch and full worldwide commercialization strategy. His team’s efforts resulted in multiple medical design excellence awards and the Johnson &
Johnson James E. Burke Marketing Excellence Award (Branding & Image Category). Mr. Geen has a Bachelor of Science in Biology from the State University of New York at Geneseo.
Erica joined INT in 2020 to lead the Chemistry efforts. She received a B.A. in Chemistry & Sociology from Washington and Jefferson College and her Ph.D. in Materials/Analytical Chemistry from the University of Utah. Erica has expertise in surface functionalization of nanoparticles, thin film deposition on glass surfaces, and alternative energy applications: specifically solid polymer electrolyte lithium-ion
batteries and PEM-type fuel cells. She has experience with SEM, TEM, TGA, DSC, DLS, AFM instrumentation for the characterization of material properties.
Don Noble has served over 30 companies as Chief Financial Officer (CFO). Don is a Partner in the Florida CFO Group where he focuses on his practice on Mergers, Acquisitions, and Divestitures. Don teaches
Corporate Finance at Hillsborough Community College, teaches Mergers and Acquisitions for The Institute for Mergers, Acquisitions, and Alliances (IMAA), and serves as a Treasurer and Board Member for two non-profits, CareerSource Tampa Bay and the Florida Association of Veteran Owned Businesses (FAVOB).
He is a veteran of the United States Air Force and during his term of service, he supported the nuclear monitoring mission of the Air Force Technical Applications Center (AFTAC).
Don received his Bachelor of Science in Finance and International Business from the Pennsylvania State
University in 1996 and his Master of Science in Finance from Boston College in 2006.
Rick plays a pivotal role in the development of INT’s technology. He specializes in biochemistry and molecular biology, with a focus on nucleic acid-related enzymes. He received his Ph.D. in Biochemistry from the University of Rochester. He later went on to be a Research Assistant Professor at the University of Rochester before joining INT in 2000.
